A recent research report published by MarkNtel Advisors states that the Global Gastroesophageal Cancer Market would grow at around 15.8% CAGR during 2022-27. Gastroesophageal (GE) cancer, a rare cancer type with no early symptoms, is generally diagnosed at later stages. It is caused mainly by heavy smoking & alcohol consumption, obesity, lifestyle changes, and diseases like gastric ulcer & gastroesophageal reflux, among others.
The primary aspects driving the Global Gastroesophageal Market include rapid approvals for the combined use of systemic therapies & new targeted agents as first-line treatments, the high efficacy of Opdivo & Keytruda (immune checkpoint inhibitors), and favorable norms for healthcare reimbursements.
Surgery remains the Standard-of-Care (SOC) for patients with esophageal Squamous Cell Carcinoma (SCC). However, the impact of traditional treatments on patient outcomes remains limited in cases like metastatic or unresectable diseases.
Nevertheless, high drug dosage that causes various side effects, including loss of appetite, hair loss, mouth & throat sores, etc., coupled with expensive treatments, are a few crucial aspects expected to hamper the fledged growth of the global market over the forecast years, further states the research report, "Global Gastroesophageal Cancer Market Analysis, 2022."
Chemotherapy & Targeted Therapies to remain Major Contributors to the Market Growth
Chemotherapy holds the largest share in the Global Gastroesophageal Cancer Market and is used widely as an adjuvant treatment for gastroesophageal cancer, owing to its higher efficiency & patient outcomes. In some cases, the combination of different chemotherapy drugs like carboplatin, capecitabine, fluorouracil (5-FU), cisplatin, & oxaliplatin with radiation therapy & surgery is prescribed in order to yield enhanced effectiveness.
Targeted therapy, another treatment for GE cancer, is gaining extensive popularity worldwide due to its superior efficiency in targeting & destroying cancer cells. HER2 & angiogenesis inhibitors are primary targeted agents used in combination with chemotherapy as the preferred treatment of GE cancer.
For HER2-positive patients, the combination of Trastuzumab & chemotherapy drugs and ramucirumab & paclitaxel are first- & second-line treatments, respectively. Numerous targeted agents like Avelumab, Andecaliximab, Ipilimumab (Yervoy), Nimotuzumab, Regorafenib, Rivoceranib, etc., are in their phase 3 development for the treatment of GE cancer, which once approved, would provide a tremendous boost to the global market.
With Rapid Drug Discoveries & Clinical Trials, Asia-Pacific to Record the Fastest Market Growth
Asia-Pacific is undergoing numerous clinical trials across different countries, especially in China, for various drugs to treat gastroesophageal cancer. China records the highest instances of GE cancer worldwide & has definite treatment options, and the only targeted drugs approved include Opdivo, Keytruda, Herceptin, AiRuiKa, & AiTan. Moreover, there are swiftly surging diagnostic procedures across the country and further in Singapore, Japan, & Indonesia, among others.
The rise in the geriatric population, sedentary lifestyles, & increased consumption of high-fat foods, i.e., leading to the increasing prevalence of gastrointestinal diseases, is driving the Asia-Pacific Gastroesophageal Market. Moreover, substantial investments by both governments & biopharma companies across the region in infrastructural developments across the healthcare sector to provide patients with specialized cancer treatments would further fuel the overall market growth over the forecast years.
The top companies in the Global Gastroesophageal Cancer Market include Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others.
Key Questions Answered in the Research Report